Roche Holding AG (OTC PINK: RHHBY) was founded in 1896 and is headquartered in Basel, Switzerland. It has 93,734 employees worldwide. It is one of the world’s largest biotechnology companies and a pioneer in the field of biopharmaceuticals & medical diagnostics. Roche’s shares are mainly traded on the Swiss exchange, and RHHBY is an ADR issued by Roche in the US pink sheet market.
Roche Holding (RHHBY):
Roche, headquartered in Basel, Switzerland, is a R&D-based global healthcare company with world-leading pharmaceutical and diagnostic businesses. As the world’s largest biotechnology company, Roche has first-class differentiated drugs in the fields of anti-tumor, immunity, anti-infection, ophthalmology and central nervous system.
Roche enjoys a leading position in the field of in vitro diagnostics and tissue-based tumor diagnosis worldwide, and is also a pioneer in the field of diabetes management. The personalized medicine advocated by Roche aims to significantly improve human health, quality of life, and patient survival through drugs and diagnosis.
Roche was founded in 1896 and has made important contributions to global health for more than a century. In the list of essential medicines of the World Health Organization, there are 24 medicines developed by Roche, including life-saving antibiotics, antimalarials and chemotherapy drugs.
In 2014, Roche had more than 88,500 employees worldwide, invested more than 8.9 billion Swiss francs in research and development, and had sales of 47.5 billion Swiss francs.
US Genentech (Genentech) is a wholly owned subsidiary of the Roche Group. In addition, Roche is also the controlling party of Chugai.
Roche Holding (RHHBY) history:
- In October 1896, F. Hoffman-Lach founded F. Hoffman-Lach Company, whose main business was pharmaceuticals
- In 1920, Baler took over the company and started the expansion of international business
- Roche came to China in 1926
- In 1929, the company started to build manufacturing and research facilities in Nutley, New Nancy, USA
- In the 1930s, the company’s chemists synthesized vitamin C, and subsequently synthesized multiple vitamins. This has had a major impact on human health.
- After World War II, the anti-infectious drug Gantrisin developed by the company became one of the most widely used prescription drugs
- In the 1950s and 1960s, the company promoted its development by vigorously expanding foreign markets and accelerating research and development
- The sedatives Librium and Valiun launched by the company in the early 1960s
- Roche returned to China in 1961
- In April 1984, the company implemented a structural reorganization plan to reduce production costs and increase market share
- In 1984, Roche returned to the Chinese mainland market
- In 1987, Roach Holdings was incorporated in the United States
- In 1989, the company sold Rotron Electronics to BMW and established Roach Holding Co., Ltd.
- In 1990, the company spent more than $2 billion to purchase 60% of Genentech ’s shares, marking the company’s entry into the biotechnology field
- In 1991, the company purchased Nicolas Laboratories, thereby occupying a larger share of the European OTC market
- In May 1994, Roche and Shanghai Sunway Co., Ltd. jointly established Shanghai Roche Pharmaceutical Co., Ltd. (Shanghai Roche Pharmaceutical Co., Ltd., which produces various types of antibiotics, antitumor drugs, antiviral drugs and central nervous system drugs, such as Rochefin® , Loxigen®, Fluorotetralone®, Yipingsu®, Medoba®, Rogaquan®, Rone®, Snapsys®, Taffeta®, etc. Some new drugs such as Xenical®, Xeloda® , Herceptin®, etc. are also in the planned production stage). In addition to the drug joint venture project, Roche’s subsidiary Givaudan Royal also established a joint venture with Shanghai Sanwei Co., Ltd. to produce Flavor products suitable for food, perfume, cosmetics, detergents, etc.
- At the end of 1995, Roche’s vitamin and fine chemical divisions cooperated with companies in Shanghai to establish two joint ventures. One is a joint venture with Shanghai Sunwei Pharmaceutical Co., Ltd. to establish Roche Sunwei (Shanghai) Vitamin Co., Ltd. to produce vitamin E for medicines, food and feed; the other is a joint venture with Shanghai No. 6 Pharmaceutical Factory to establish Roche Taishan (Shanghai) Vitamin Products Co., Ltd. A company that produces vitamin A for medicine, food and feed
- In December 1995, the holding company-Roche (China) Co., Ltd. was established
- At the end of 1996, Roche and Shanghai Xinya Pharmaceutical Co., Ltd. jointly established Roche Xinya (Shanghai) Vitamin Co., Ltd., which focuses on the production of vitamin B6.
- In 1997, Corange was acquired
- On December 16, 1997, Roche and Wuxi Zhongya Chemical Co., Ltd. jointly established Roche Zhongya (Wuxi) Citric Acid Co., Ltd., with an annual output of 20,000 tons of citric acid and sodium citrate.
- In 1999, Genentech was fully privatized
- In 1999, Roche occupied 40% of the world vitamin market
- At the end of 2002, Roche sold his vitamin business to the Dutch pharmaceutical group DSM
- On March 26, 2009, Roche completed the acquisition of 44% of the unowned shares of the biopharmaceutical company Genentech for approximately US$46.8 billion and fully owned the company
- On August 25, 2014, Roche Pharmaceuticals agreed to acquire InterMune, a US biotechnology company, for approximately US$8.3 billion in cash, and will obtain pirfenidone, a drug used to treat idiopathic pulmonary fibrosis.
In terms of new drugs, such as Rochefene, Roxacine, Fluoroterolone, Yipingsu, Metopa, Rogaquan, Rone, and Xiaoxi. Some new drugs such as Xenical, Xeloda, Herceptin, Tamiflu, etc. are in the planned production stage.
Roche’s areas of expertise:
Roche is a global leader in the following areas:
- Anti-tumor field
- Transplantation field
- Virology field
- Other key disease areas
- Autoimmune disease
- Central Nervous System Disease
- Diagnostic field